Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).

ABSTRACT:

Background

The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast cancer. Recently, studies showed that cyclin-dependent kinase (CDK) 4/6 inhibitor, when added to endocrine therapy, had improved the outcomes of patients with advanced ER-positive HER2-negative breast cancer. However, the disease often progresses following a period of treatment response. In a subset of patients, disease progression may occur at limited sites, i.e., oligoprogressive disease (OPD). In the past few years, stereotactic radiotherapy (SRT) has emerged as a safe and effective treatment for advanced cancer when delivered to limited metastatic sites. Hence, it is worth investigating the role of SRT in the setting of oligoprogressive breast cancer.<

SUBMITTER: Alomran R 

PROVIDER: S-EPMC7989018 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature